💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Cytokinetics debuts two new pipeline candidates at R&D Day

Published 10/16/2018, 08:52 AM
© Reuters.  Cytokinetics debuts two new pipeline candidates at R&D Day
AMGN
-
CYTK
-
  • Cytokinetics (NASDAQ:CYTK) is hosting its R&D Day in New York City today. Highlights:
  • Two new pipeline candidates will be advanced into Phase 1 development by year-end, a novel cardiac troponin activator discovered with research partner Amgen (NASDAQ:AMGN) and a cardiac myosin inhibitor, CK-274, discovered internally.
  • Partner Amgen plans to launch a Phase 1 study of cardiac troponin activator AMG 594 soon. The design of a Phase 2 study in heart failure is being discussed.
  • Enrollment in a Phase 2 study of reldesemtiv in ALS should be completed by year-end with topline data expected in H1 2019.
  • A second Phase 3 trial evaluating omecamtiv mecarbil in heart failure patients should launch by year-end. Enrollment in the first study should be completed in H1 2019.
  • Now read: Week 39 Breakout Forecast: Short-Term Picks To Give You An Edge


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.